Orphazyme Inc. (NASDAQ: ORPH) stock gained by 24.62% at last close while the ORPH stock price surged by 9.27% in the pre-market trading session. Orphazyme is a late-stage pharmaceutical business that is pioneering the use of heat shock proteins to cure uncommon illnesses. ORPH is using heat shock protein (HSP) amplification to discover and market new treatments for illnesses characterized by protein misfolding, aggregation, and lysosomal dysfunction.
>> 7 Top Picks for the Post-Pandemic Economy <<
What is happening?
Orphazyme has received notices from The Goldman Sachs Group, pursuant to Section 38 of the Danish Capital Markets Act, that Now the Goldman Sachs Group’s accumulated holding of shares and financial instruments boosted to 5.58 percent of Orphazyme’s share capital and voting rights as of June 16, 2021. The Goldman Sachs Group’s cumulative ownership of shares and financial instruments in Orphazyme has been decreased to less than 5% of the shares and voting rights as of June 17, 2021.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Orphazyme’s “important shareholder statement”, on the other hand, signifies almost nothing to investors.
It would be one thing if a big investment bank, such as Goldman Sachs, had grown its holdings in Orphazyme and kept them. That may have suggested that the modest pharmaceutical company’s chances were increasing. However, Goldman Sachs’ action was only temporary in this situation.
Read More
Furthermore,
More crucially, Goldman Sachs momentarily raised its position in Orphazyme before the US Food and Drug Administration announced on June 18 that arimoclomol was not approved for the treatment of the uncommon illness Niemann-Pick Disease Type C. The FDA denial was a major blow for Orphazyme, and the biotech stock plummeted last week as a result.
Orphazyme is still hoping to get arimoclomol approved in Europe in early 2022. Orphazyme is also weighing whether it should continue to pursue FDA clearance for the experimental medication.
